May 05,2021

Nemaura Medical Announces Order for 200,000 sugarBEAT® Sensors

Based on the success of the soft launch in the U.K., the Company is advancing discussions for joint launches in Germany, Saudi Arabia and UAE

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
May 06,2021

Differences in Glucose Readings Between Right Arm and Left Arm Using a Continuous Glucose Monitor

Continuous glucose monitoring (CGM) devices are used for evaluating real-time glucose levels to optimize diabetes management. There is limited information, however, on whether readings differ when a device is placed on the right versus the left arm. This study evaluated the mean difference in glucose levels between the right and left arm and the effect of unilateral arm exercise on this difference. The effect of an intermittent fasting diet on body fat percentage was also evaluated.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
May 06,2021

BD Announces Intent to Spin Off Diabetes Care Business to Enhance Focus on Innovation and Priority Growth Markets

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced its board of directors has unanimously authorized management to proceed with a plan to spin off the company's Diabetes Care business as an independent, publicly traded company ("NewCo").

View Analyst & Ambassador Comments
Go to original news
May 06,2021

Nemaura Medical Announces Progress on Listing of sugarBEAT® For Reimbursement in Germany

Nemaura Medical, Inc., a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced progress with the German regulatory authority (GBA) to achieve reimbursement for its sugarBEAT® device.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
May 06,2021

BD Announces Second Fiscal Quarter Results; Reaffirms Fiscal 2021 Guidance

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $4.9 billion for the second fiscal quarter ended March 31, 2021....

View Analyst & Ambassador Comments
Go to original news
May 06,2021

Algorithms for Automated Insulin Delivery: An Overview

The technology needed to “close the loop,” that is, a system for continuous glucose monitoring and a pump that infuses insulin, are only 2 of the 3 components needed for each system for automated insulin delivery (AID), the other is a “translation” of the glucose information into the appropriate amount of insulin to be applied at a given point in time to keep glucose levels in the body in the target range.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
May 06,2021

Roche collaborates with Lilly to support people with diabetes on insulin pen therapy

Under the terms of the collaboration agreement, data from Lilly’s connected insulin pen solution will become part of Roche’s open ecosystem through the mySugr app in several countries outside the U.S. This integration will follow the recent launch of the Novo Nordisk smart insulin pen data integration into the mySugr app. 

COLLABORATION PARTNERSHIP

#connected device

#insulin pen

#mobile app

View Analyst & Ambassador Comments
Go to original news
May 06,2021

Insulet Reports First Quarter 2021 Revenue Increase of 27% Year-Over-Year

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months ended March 31, 2021.

View Analyst & Ambassador Comments
Go to original news
May 07,2021

Mumbai-based Fitterfly is providing 360-degree guidance to help people control diabetes

Founded in 2016, digital therapeutics startup Fitterfly offers guidance on nutrition, exercise, sleep, stress, and other factors to help people better manage lifestyle diseases, including diabetes, PCOS, and obesity, among others.

PRODUCT

#dtx

View Analyst & Ambassador Comments
Go to original news
May 08,2021

Adverse Event Data for Years 2018 to 2020 for Diabetes Devices

Unlike performance evaluations, which are often conducted under ideal conditions, adverse events occur during actual device use for people with diabetes. This report summarizes the number of adverse events for the years 2018 to 2020 for the 3 diabetes devices: blood glucose meters (BG), continuous glucose monitors (CGM), and insulin pumps.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES